Fulcrum Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FULC research report →
About the company
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia.
- CEO
- Alexander C. Sapir
- IPO
- 2019
- Employees
- 45
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $207.79M
- P/E
- -3.34
- P/S
- 0.00
- P/B
- 0.88
- EV/EBITDA
- -2.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.80%
- ROIC
- -25.50%
- Revenue
- $0 · -100.00%
- Net Income
- $-74,880,000 · -669.97%
- EPS
- $-1.18 · -637.50%
- Op Income
- $-84,769,000
- FCF YoY
- -2319.03%
- 52W High
- $15.74
- 52W Low
- $2.83
- 50D MA
- $5.49
- 200D MA
- $8.45
- Beta
- 3.00
- Avg Volume
- 2.27M
Get TickerSpark's AI analysis on FULC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Banks Sonja | other | 32,000 |
| Jun 30, 26 | Dorton Katina | other | 32,000 |
| Jun 30, 26 | Gould Robert J | other | 32,000 |
| Jun 30, 26 | Haviland Kate | other | 32,000 |
| Jun 30, 26 | King Rachel K. | other | 32,000 |
| Jun 30, 26 | GERAGHTY JAMES A | other | 32,000 |
| Jun 30, 26 | Hill Colin | other | 32,000 |
| Jun 30, 26 | Ezekowitz Alan | other | 32,000 |
| Jun 26, 26 | Ezekowitz Alan | sell | 18,000 |
| Apr 23, 26 | Lehrer-Graiwer Joshua | other | 64,000 |
Our FULC coverage
Recent articles, reports, and earnings notes.
No research on FULC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FULC report →Similar companies
Peers in the same neighborhood.